Generic Industry Likely To See Increasing Geographic Diversification - Barr
This article was originally published in PharmAsia News
Executive Summary
The generic drug industry has myriad reasons to expand into non-U.S. markets and will continue to do so, according to Barr CEO Bruce Downey
You may also be interested in...
AB Or Not AB? Barr & Sandoz Ponder The Biogeneric Substitution Question
Generic manufacturers may not want substitutability for follow-on biologics, Barr CEO Bruce Downey said Sept. 19 at the Generic Pharmaceutical Association Annual Policy Conference in Washington, D.C
Generic Mobic, Celexa Launches Are Not Indicative Of Price Erosion – Teva
The deep discounts seen with some recent high profile generic launches are not reflective of an eroding generic pricing environment, Teva maintains
Barr’s Rationale For Pliva Merger: Business Synergy, Biogenerics Leadership
Barr is highlighting its complementary product portfolio and business model in its efforts to ward off competition from Actavis to acquire Pliva